What 438 FDA Complete Response Letters Actually Say
The most common reason the FDA refuses a drug application is no longer the science behind the drug; it is the quality practices in a facility. Letter after letter, the agency is saying so in near-identical sentences. This report classifies every Complete Response Letter the FDA has published, a total of 438 refusals spanning from 2002 to 2026. Using the state of the art semantic models, we came up with eleven rejection categories and sixteen GMP sub-themes, trended by year.
Inside you will find the 4 most common sentences cited again and again by the agency for the refusals. The 12 year view is broken down into themes showing facility readiness climbing while the classic CMC themes fade gradually. You will be surprised to learn why the labelling numbers mean the opposite of what they seem to and the two ways these CRLs are routinely misread. Finally, it closes with six specific checks a quality team can run before its next filing, drawn from the specifics found in these letters. The full report, with every figure and the complete checklist, is available as a download below.
About Atlas
Atlas is a regulatory intelligence platform built for pharmaceutical and medical device quality and regulatory teams. It structures the public FDA record, inspection outcomes, Form 483 observations, warning letters, establishment inspection reports and Complete Response Letters, alongside international agency records, so a team can benchmark its sites, investigators and deficiency history against the published record before an inspection rather than after one. The Complete Response Letter analysis behind this report is free to explore and export at atlas-compliance.ai.
